AbbVie Inc. (4AB.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:44AM CEST. Market open.
| Previous Close | 159.44 |
| Open | 155.06 |
| Bid | 155.72 x 60000 |
| Ask | 157.22 x 60000 |
| Day's Range | 155.06 - 155.06 |
| 52 Week Range | 119.00 - 168.80 |
| Volume | |
| Avg. Volume | 230 |
| Market Cap | 274.557B |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 61.05 |
| EPS (TTM) | 2.54 |
| Earnings Date | Apr 26, 2024 |
| Forward Dividend & Yield | 5.84 (3.66%) |
| Ex-Dividend Date | Apr 12, 2024 |
| 1y Target Est | 127.01 |
ZacksWill Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
© 2024 Yahoo. All rights reserved.